Nutrition composition

Patent metadata

Field	Value
Publication number	US-9629386-B2
Application number	US-201113152574-A
Country	US
Kind code	B2
Filing date	Jun 3, 2011
Priority date	Dec 5, 2008
Publication date	Apr 25, 2017
Grant date	Apr 25, 2017

Abstract

The present invention can provide a nutrition composition useful for patients with renal diseases, which has an effective prophylactic or improving effect for various symptoms of malnutrition, inflammation, arteriosclerosis, abnormal lipid metabolism and oxidative stress, associated with renal diseases, or for diabetic nephropathy.
The nutrition composition of the present invention m contains one or more kinds of free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, and a lipid comprising ω-3 fatty acid and ω-6 fatty acid at a weight ratio (ω-6 fatty acid to ω-3 fatty acid) of 0.5-5.5. In addition, the composition further contains a soybean protein or a hydrolysate thereof together with the aforementioned lipid or instead of the aforementioned lipid.

First claim

The invention claimed is:

1. A method for preventing or improving at least one symptom selected from the group consisting of malnutrition, inflammation, arteriosclerosis, abnormal lipid metabolism and oxidative stress, associated with renal disease, comprising:
administering, to a subject in need thereof, 50 kcal to 2000 kcal of a nutrition composition for an adult per day,
wherein the nutrition composition comprises at least one free amino acid selected from the group consisting of valine, leucine, isoleucine, and histidine, a lipid comprising at least one ω-3 fatty acid and at least one ω-6 fatty acid in a weight ratio of ω-6 fatty acid to ω-3 fatty acid of 0.5 to 5.5, a carbohydrate, and a soybean protein or a hydrolysate thereof,
in the nutrition composition, the total amount of protein and peptide is not more than 3.5 g per 100 kcal of the nutrition composition, the soybean protein or a hydrolysate thereof comprises 20 wt % to 100 wt % of any proteins or peptides present, a content of the protein and peptide is 6 calorie % to 10 calorie %, a content of the lipid is 30 calorie % to 32 calorie %, and a content of the carbohydrate is 60 calorie % to 62 calorie %, and
the subject in need thereof is a patient having at least one symptom selected from the group consisting of malnutrition, inflammation, arteriosclerosis, abnormal lipid metabolism and oxidative stress, associated with renal disease.

2. A method according to claim 1 , wherein the nutrition composition further comprises 5 mg to 150 mg of vitamin C, per 100 kcal of the composition.

3. A method according to claim 1 , wherein the nutrition composition comprises the at least one free amino acid in an amount of 0.1 g to 10 g per 100 kcal of the composition.

4. A method according to claim 1 , wherein the ω-3 fatty acid is at least one fatty acid selected from the group consisting of α-linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid.

5. A method according to claim 1 , wherein the ω-6 fatty acid is at least one fatty acid selected from the group consisting of linoleic acid, γ-linolenic acid, stearidonic acid, and arachidonic acid.

6. A method according to claim 1 , wherein the lipid comprises 10 wt % to 65 wt % of medium chain fatty acid oil.

7. A method according to claim 1 , wherein the nutrition composition further comprises not less than 1 mg of vitamin E, per 100 kcal of the nutrition composition.

8. A method according to claim 1 , wherein the nutrition composition further comprises 5 mg to 150 mg of vitamin C and not less than 1 mg of vitamin E, per 100 kcal of the nutrition composition.

9. A method according to claim 1 , wherein the nutrition composition further comprises 2.5 μg to 45 μg of selenium and 1 mg to 9 mg of zinc, per 100 kcal of the nutrition composition.

10. A method according to claim 1 , wherein the subject in need thereof is a patient having at least one symptom selected from the group consisting of inflammation, arteriosclerosis, abnormal lipid metabolism and oxidative stress, associated with renal disease, and the nutrition composition is administered to the subject in an amount sufficient to improve the one or more symptoms.

11. A method according to claim 10 , wherein the subject in need thereof is a patient under a dialysis treatment.

12. A method according to claim 10 , wherein the subject is a human adult.

13. A method for preventing or improving diabetic nephropathy, comprising:
administering, to a subject in need thereof, 50 kcal to 2000 kcal of a nutrition composition for an adult per day,
wherein the nutrition composition comprises at least one free amino acid selected from the group consisting of valine, leucine, isoleucine, and histidine, a lipid comprising at least one ω-3 fatty acid and at least one ω-6 fatty acid in a weight ratio of ω-6 fatty acid to ω-3 fatty acid of 0.5 to 5.5, a carbohydrate, and a soybean protein or a hydrolysate thereof,
in the nutrition composition, the total amount of protein and peptide is not more than 3.5 g per 100 kcal of the nutrition composition, the soybean protein or a hydrolysate thereof comprises 20 wt % to 100 wt % of any proteins or peptides present, a content of the protein and peptide is 6 calorie % to 10 calorie %, a content of the lipid is 30 calorie % to 32 calorie %, and a content of the carbohydrate is 60 calorie % to 62 calorie %, and
the subject in need thereof is a patient with diabetic nephropathy.

14. A method according to claim 13 , wherein the nutrition composition comprises the at least one free amino acid in an amount of 0.1 g to 10 g per 100 kcal of the nutrition composition.

15. A method according to claim 13 , wherein the ω-3 fatty acid is at least one fatty acid selected from the group consisting of α-linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid.

16. A method according to claim 13 , wherein the ω-6 fatty acid is at least one fatty acid selected from the group consisting of linoleic acid, γ-linolenic acid, stearidonic acid, and arachidonic acid.

17. A method according to claim 13 , wherein the lipid comprises 10 wt % to 65 wt % of medium chain fatty acid oil.

18. A method according to claim 13 , wherein the nutrition composition further comprises not less than 1 mg of vitamin E, per 100 kcal of the nutrition composition.

19. A method according to claim 13 , wherein the nutrition composition further comprises 5 mg to 150 mg of vitamin C and not less than 1 mg of vitamin E, per 100 kcal of the nutrition composition.

20. A method according to claim 13 , wherein the nutrition composition further comprises 2.5 μg to 45 μg of selenium and 1 mg to 9 mg of zinc, per 100 kcal of the nutrition composition.

21. A method according to claim 13 , wherein the nutrition composition further comprises 5 mg to 150 mg of vitamin C, per 100 kcal of the nutrition composition.

Assignees

• Somekawa Shinji
• Mine Tomoyuki
• Hayashi Naoki
• Ajinomoto Kk

Inventors

• Somekawa Shinji
• Mine Tomoyuki
• Hayashi Naoki

Classifications

• A61P39/06

  Free radical scavengers or antioxidants · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title